Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status.
- Author:
Fei-jiao GE
1
;
Jian-zhi LIU
;
Shan-shan LI
;
Yan WANG
;
Lie-jun LIU
;
Kai YAO
;
Chuan-hua ZHAO
;
Ya-Li FU
;
Li LIN
;
Jian-ming XU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antibodies, Monoclonal; therapeutic use; Antineoplastic Agents; therapeutic use; Antineoplastic Agents, Phytogenic; therapeutic use; Camptothecin; analogs & derivatives; therapeutic use; Colorectal Neoplasms; genetics; pathology; surgery; therapy; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Genes, ras; Humans; Liver Neoplasms; secondary; therapy; Lung Neoplasms; secondary; therapy; Male; Middle Aged; Mutation; Organoplatinum Compounds; therapeutic use; Receptor, Epidermal Growth Factor; immunology; Retrospective Studies; Survival Rate
- From: Chinese Journal of Oncology 2013;35(4):273-276
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the correlation of clinical effect and prognosis between patients with metastatic colorectal cancer (mCRC) and different K-ras status.
METHODSThe clinical characteristics, chemotherapeutic regimens and survival of 153 mCRC patients with different K-ras status were analyzed retrospectively.
RESULTSThe median overall survival (OS) in patients without K-ras mutation were 31.7 months, significantly longer than 21.3 months in the patients with K-ras mutation (P = 0.037). The median progression-free survival (PFS) and OS in patients who received chemotherapy followed by anti-EGFR antibody treatment were 11.5 and 39.3 months, respectively, significantly longer as compared with the PFS and OS in those received chemotherapy in combination with anti-EGFR antibody concomitantly (5.7, P = 0.02, and 28.7 months, P = 0.034, respectively).
CONCLUSIONSK-ras status is a prognostic biomarker for mCRC patients treated with anti-EGFR antibody. The combination settings of anti-EGFR in combination with chemotherapy may improve survival of mCRC patients with wild-type K-ras status.
